The German biotechnology company CureVac announced that in a few months it will start clinical trials of a second generation vaccine against Covid-19.
The company has released data showing that its second vaccine, called CV2CoV, produced antibodies in animals (monkeys) comparable to those of the Pfizer / BioNtech vaccine. The effectiveness of the new vaccine seems to be greater than that of the first, which was eventually abandoned.
In October, CureVac stopped its very advanced effort to develop its first coronavirus (CvnCoV) vaccine, following disappointing results in final human trials that showed only 47% effectiveness. This prompted her to withdraw her request to the European Medicines Agency (EMA) for approval of her vaccine, as well as the expiration of her agreement with the EU on the supply of vaccines.
The company is now focusing on working with major pharmaceutical company GSK to develop an improved mRNA vaccine, according to Reuters.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
